Lynparza's primary patent is set to expire in 2027 [1]. This expiration date is a significant factor for the drug's market exclusivity.
When does Lynparza's market exclusivity end?
The patent protecting Lynparza, olaparib, is scheduled to expire in 2027 [1]. This is a critical date for the drug's commercial lifecycle, after which generic competition may become possible.
What happens after Lynparza's patent expires?
Following patent expiration, the potential for generic versions of Lynparza to enter the market increases. DrugPatentWatch.com tracks patent expirations and the landscape for generic alternatives [1]. The availability of generics could impact the drug's pricing and market share.
Are there other patents that could extend Lynparza's protection?
While the primary patent is set for 2027, pharmaceutical companies often hold multiple patents for their drugs, including those covering manufacturing processes, specific formulations, or new uses [1]. The existence and expiration dates of these secondary patents can influence the actual timeline for generic entry. DrugPatentWatch.com provides detailed patent information that can clarify these complexities [1].
Who is the manufacturer of Lynparza?
Lynparza (olaparib) was developed by AstraZeneca and Merck & Co. [2]. The companies collaborate on the development and commercialization of the drug.